|
Mutation Information
|
Mutation Site
|
I169L |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204V+rt.S202G+rt.I169L+rt.L180M |
|
Relevant Drug
|
lamivudine (LAM);entecavir (ETV) |
Literature Information
|
PubMed PMID
|
17239478
|
|
Disease
|
Chronic hepatitis B;
Liver cirrhosis
|
|
Published Year
|
2007 |
|
Journal
|
Journal of hepatology |
|
Title
|
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. |
|
Author
|
Villet S,Ollivet A,Pichoud C,Barraud L,Villeneuve JP,Trépo C,Zoulim F |
|
Evidence
|
The triple mutant (rtL180M+S202G+M204V), which became the dominant strain at the end of entecavir and at the beginning of lamivudine+adefovir therapies, displayed with the rtI169L+L180M+S202G+M204V the highest resistance to entecavir (≈1300- and ≈1200-fold compared to wt HBV).
|
|
|
HBV Mutation Detail Information